We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04623242
Recruitment Status : Completed
First Posted : November 10, 2020
Results First Posted : September 22, 2022
Last Update Posted : September 22, 2022
Sponsor:
Collaborators:
Eli Lilly and Company
Hoffmann-La Roche
Alzheimer's Association
National Institute on Aging (NIA)
Avid Radiopharmaceuticals
Accelerating Medicines Partnership (AMP)
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:

The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.

This is an analysis study for an MPRP: DIAN-TU-001 Master NCT01760005


Condition or disease Intervention/treatment Phase
Alzheimers Disease Dementia Alzheimers Disease, Familial Drug: Gantenerumab Drug: Solanezumab Drug: Matching Placebo (Gantenerumab) Drug: Matching Placebo (Solanezumab) Phase 2 Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 194 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Interventional
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease
Actual Study Start Date : December 2012
Actual Primary Completion Date : November 22, 2019
Actual Study Completion Date : March 6, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Gantenerumab Drug: Gantenerumab
Subcutaneously every 4 weeks at escalating doses
Other Name: RO4909832

Experimental: Solanezumab Drug: Solanezumab
Intravenous infusion every 4 weeks at escalating doses
Other Name: LY2062430

Placebo Comparator: Matching placebo (Gantenerumab) Drug: Matching Placebo (Gantenerumab)
Subcutaneous injection of placebo every 4 weeks

Placebo Comparator: Matching Placebo (Solanezumab) Drug: Matching Placebo (Solanezumab)
Intravenous infusion of placebo every 4 weeks




Primary Outcome Measures :
  1. Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); [ Time Frame: Baseline through Week 260 ]

    Multivariate Disease Progression Model adjusted for Estimated Years to Onset (EYO)and includes all timepoints up to treatment discontinuation. The treatment effect is reported relative to the mutation positive placebo arm.

    Multivariate Cognitive Endpoint comprising: (i) Wechsler Memory Scale-Revised Logical Memory Delayed Recall Test (MEMUNITS), (ii) Wechsler Adult Intelligence Scale Digit Symbol Substitution Test (WAIS), (iii) Mini-Mental State Examination (MMSE), and (iv) International Shopping List Task (ISLT). Measurements for each test were normalized using the mean (SD) at DIAN-TU-001 baseline for mutation negative subjects. Higher scores indicate more favourable cognitive performance.



Secondary Outcome Measures :
  1. Gantenerumab: Rate of Change Over Time- Clinical Dementia Rating Sum of Boxes (CDR-SB) [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    CDR-SB score is considered a more detailed quantitative general index of cognition and function, and provides more information than the global CDR score in patients with mild dementia

    Scores range from 0-18 with lower scores showing more favorable cognitive function.


  2. Gantenerumab: Rate of Change Over Time- Functional Assessment Scale (FAS) [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]
    The Functional Assessment Scale is to be administered and completed by the study partner about subjects for whom they care. This scale measures instrumental activities of daily living such as preparing balanced meals and managing personal finances. The intent of the FAS is to assess change in an individual's functional activities, relative to previously attained abilities, that are caused by cognitive dysfunction. If the study partner indicates that the subject no longer performs a particular task, it is reasonable to probe further and ask if they think the subject could still do the task. This will help tease out the relevant cognitive impairment

  3. Gantenerumab: Imaging Measures Composite [11C] PiB Partial Volume Corrected Regional Spread Function Standardized Uptake Value Ratio - Composite [ Time Frame: Baseline, Weeks 52, 104 and 208 ]
    In vivo quantification of β-amyloid deposition using positron emission tomography. This measure is a composite of brain regions. Higher scores indicate worse disease stage.

  4. Solanezumab: Clinical Measures- Clinical Dementia Rating (CDR) [ Time Frame: Baseline and Weeks 52, 104, 156, and 208 ]
    Clinical Dementia Rating - Global Score - Number of Subjects with an Increase from Baseline by Visit

  5. Solanezumab: Clinical Measures- CDR Sum of Boxes (CDR-SB) [ Time Frame: Baseline and Weeks 52, 104, 156, and 208 ]

    CDR-SB score is considered a more detailed quantitative general index and provides more information than the global CDR score in patients with mild dementia

    Scores range from 0-18 with lower scores showing more favorable cognitive function.


  6. Solanezumab: Clinical Measures- Geriatric Depression Scale (GDS) [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    The Geriatric Depression Scale (GDS) is a self-report measure of depression in older adults. Users respond in a "Yes/No" format. Of the 15 items, 10 indicate the presence of depression when answered positively while the other 5 are indicative of depression when answered negatively.

    Scores range from 0-15 for completed questionnaires. A score of 88 is recorded for participants unable to complete the test.

    Lower scores show more favorable outcome.


  7. Solanezumab: Clinical Measures- Neuropsychiatric Inventory Questionnaire (NPI-Q) [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    The questionnaire is to be administered and completed by the study partner about patients for whom they care. Each of the 12 NPI-Q domains contains a survey question that reflects cardinal symptoms of that domain. Initial responses to each domain question are "Yes"(present) or "No" (absent). If the response to the domain question is "No", the study partner goes to the next question. If "Yes", the study partner then rates both the Severity of the symptoms present within the last month on a 3-point scale and the associated impact of the symptom manifestations on them (i.e. Caregiver Distress) using a 5-point scale. The NPI-Q provides symptom 'Severity' and 'Distress' ratings for each symptom reported, and total 'Severity' and 'Distress' scores reflecting the sum of individual domain scores.

    Scores range from 0-36 with lower scores indicating more favorable cognitive function.


  8. Solanezumab: Clinical Measures- Functional Assessment Scale (FAS) [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    The Functional Assessment Scale is to be administered and completed by the study partner about subjects for whom they care. This scale measures instrumental activities of daily living such as preparing balanced meals and managing personal finances. The intent of the FAS is to assess change in an individual's functional activities, relative to previously attained abilities, that are caused by cognitive dysfunction. If the study partner indicates that the subject no longer performs a particular task, it is reasonable to probe further and ask if they think the subject could still do the task. This will help tease out the relevant cognitive impairment

    Scores range from 0-30 with lower scores indicate more favorable cognitive performance


  9. Solanezumab: Clinical Measures- Mini-Mental Status State Examination (MMSE) [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    MMSE is a brief, quantitative measure of cognitive status in adults used to screen for cognitive impairment, to estimate the severity of cognitive impairment at a given point in time, to follow the course of cognitive changes in an individual over time, and to document an individual's response to treatment.

    Scores range from 0-30 and higher scores indicate more favorable cognitive function.


  10. Solanezumab: Cognitive Measures- International Shopping List Task 30-Minute Delayed Recall [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    Classic list-learning test that measures verbal learning & memory.

    Scores range from 0-12 with higher scores indicating more favorable cognitive performance.


  11. Solanezumab: Cognitive Measures- Groton Maze Learning Test 30 Minute Delayed Recall [ Time Frame: Baseline, Week 52, 104, 156, 208 and 260 ]
    The Groton Maze Learning Test 30 minute delayed recall measures episodic memory. The primary outcome is the number of errors made during recall of the previously memorized pathway from the Groton Maze Learning Test. The minimum score is 0 errors and the max is 999. Lower scores indicate better cognitive performance.

  12. Solanezumab: Cognitive Measures- Groton Maze Learning Test Delayed Reversed Recall [ Time Frame: Baseline, Week 52, 104, 156, 208 and 260 ]

    The Groton Maze Learning Test measures executive function using a maze learning paradigm. A 10 x 10 grid of tiles is presented to the participant on the screen. A 28-step pathway is hidden among these tiles. A blue tile indicates the start and a tile with red circles indicates the finish. The participant must move one step at a time from the start toward the end by touching a tile next to their current location. If the correct move is made a green checkmark appears and if the move is incorrect a red cross is revealed. Once completed, they are returned to the start location to repeat the test and must try to remember the pathway they have just completed. "Delayed Reverse Recall" measures spatial working memory.

    The outcome is the number of errors made with the range of 0-999. Lower scores indicate better cognitive performance.


  13. Solanezumab: Cognitive Measures- Trailmaking Test Part A [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    Trail Making test taps attention, processing speed, and executive function. Part A consists of 25 circles numbered 1 through 25 distributed over a white sheet of standard document-sized paper. The subject is instructed to connect the circles with a drawn line as quickly as possible in ascending numerical order without lifting their pen.

    The subject's performance is judged in terms of the time, in seconds, required to complete each trail (Max time 150 seconds). Lower scores indicate more favorable cognitive function.


  14. Solanezumab: Cognitive Measures- Trailmaking Test Part B [ Time Frame: Baseline, Weeks 52, 104, 156, 208 and 260 ]

    This test taps attention, processing speed, and executive function and depends on visuo-motor and perceptual-scanning skills and also requires considerable cognitive flexibility in shifting from number to letter sets under time pressure. Part B consists of 25 circles, but these circles contain either numbers (1 through 13) or letters (A through L). The subject must connect the circles while alternating between numbers and letters in an ascending order (e.g., A to 1; 1 to B; B to 2; 2 to C).

    The subject's performance is judged in terms of the time, in seconds, required to complete each Trail (Max of 300 seconds). Lower scores indicate more favorable cognitive function.


  15. Solanezumab: Cognitive Measures- WAIS-R Digit-Symbol Substitution Test [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    This test engages multiple cognitive abilities, including attention, psychomotor speed, complex scanning, visual tracking, and immediate memory.

    Scores range from 0-93 with higher scores indicate more favorable cognitive function.


  16. Solanezumab: Cognitive Measures- WMS-R Digit Span Backward [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    Widely used measure of working memory (or attention) in which the subject is read number sequences of increasing length and then asked to repeat each sequence backward. The primary measure of performance is the number of digit sequences correctly reversed.

    The unit of measure is number of digit sequences correctly recalled and ranges from 0-12. Higher scores indicate more favorable cognitive function.


  17. Solanezumab: Cognitive Measures- WMS-R Digit Span Forward [ Time Frame: Baseline, Weeks 52, 104, 156, 208 and 260 ]

    This is a widely-used test of working memory in which the subject is read number sequences of increasing length and asked to repeat them. The total score is the number of sequences correctly repeated.

    The unit of measure is number of digit sequences correctly recalled and ranges from 0-12. Higher scores indicate more favorable cognitive function.


  18. Solanezumab: Cognitive Measures- Raven's Progressive Matrices (Set A) [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    This is a measure of fluid intelligence. This test is used to get an estimate of the subjects IQ at baseline. Subjects are asked to complete a visual pattern by circling one of six response choices.

    Scores range from 0-12 with higher scores indicating more favorable cognitive performance.


  19. Solanezumab: Cognitive Measures- Category Fluency (Animals) [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    Category Fluency is a widely used measure of semantic memory (verbal fluency, language). The subject is asked to name different exemplars of a given semantic category (animals), and the number of unique exemplars named is scored.

    Higher scores indicate more favorable cognitive function.


  20. Solanezumab: Cognitive Measures- Category Fluency (Vegetables) [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    Category Fluency is a widely used measure of semantic memory (verbal fluency, language). The subject is asked to name different exemplars of a given semantic category (vegetables), and the number of unique exemplars named is scored.

    Higher scores indicate more favorable cognitive function.


  21. Solanezumab: Cognitive Measures- WMS-R Logical Memory Delayed Recall Test [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    Measure of delayed recall (episodic memory) of a story read to the subject at the beginning of the testing session and subject is asked to relay the story 20 minutes later.

    Scores range from 0-25 with higher scores indicating more favorable cognitive performance.


  22. Solanezumab: Cognitive Measures- WMS-R Logical Memory Immediate Recall Test [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]

    This test assesses the ability to recall a short story. The subject is read a short story and immediately after hearing the story, the subject is asked to retell the story from memory.

    Scores range from 0-25 with higher scores indicating more favorable cognitive performance.


  23. Solanezumab: Cognitive Measures- Composite Including: Alternative Multivariate Composite: (1) Digit Span Backwards; (2) Logical Memory (Immediate); (3) Trailmaking B; (4) Category Fluency (Animals) [ Time Frame: Baseline through Week 260 ]

    Multivariate Disease Progression Model adjusted for estimated years from symptom onset (EYO) and includes all time points up to treatment discontinuation. The treatment effect for Solanezumab is reported relative to the mutation positive placebo arm.

    This alternative multivariate endpoint includes four tests: Logical Memory Immediate Recall, Digit Span Backward Recall, Category Fluency (Animals), Trailmaking Test Part B. Measurements for each test will be normalized using the mean (SD) at DIAN-TU-001 baseline among mutation negative subjects before being analyzed. For the Trailmaking Test B, the scores will be multiplied by -1 as higher scores indicate worse performance; whereas for the other three, lower scores indicate worse performance. Therefore, on the standardized endpoints, lower scores indicate worse performance.


  24. Solanezumab: Imaging Measures- Brain Amyloid Load as Measured by [11C]PiB-PET Non-partial Volume Corrected [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    PiB Standardized Uptake Value Ratio ([11C]PiB SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions dervived via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.

  25. Solanezumab: Imaging Measures- Brain Amyloid Load as Measured by Florbetapir PET [ Time Frame: Weeks104 and 208 ]
    Florbetapir Standardized Uptake Value Ratio ([18F]AV-45 SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions derivved via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.

  26. Solanezumab: Imaging Measures- Brain Glucose Metabolism as Measured by Fluorodeoxyglucose (FDG)-PET Non-partial Volume Corrected [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    FDG Standardized Uptake Value Ratio ([18F]FDG SUVR) is the most common quantitative method used to make regional comparisons within a subject as well as between subjects and computed as the degree of radiotracer uptake in a target region of interest (regions derivved via automated segmentation using FreeSurfer) with respect to a reference region. In amyloid and tau imaging, SUVR is typically generated using some portion or the entire cerebellum as a reference because cerebellum is not affected until late in the progression of AD.

  27. Solanezumab: Imaging Measures- Brain Atrophy as Measured by Cortical Thickness of Regions of Interest - Precuneus Region [ Time Frame: Baseline and Weeks 52, 104, 156 and 208 ]
    Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. For the clinical trial we examined cortical thickness values in prespecified regions of interest known to show atrophy in autosomal dominant Alzheimer Disease. Higher measurements are more favorable.

  28. Solanezumab: Imaging Measures- Volumetric MRI Combined Total Volume Corrected for Head Size - Hippocampus Volume [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]
    Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. For the clinical trial we examined volume values in prespecified regions of interest known to show atrophy in autosomal dominant Alzheimer Disease.

  29. Solanezumab: Imaging Measures- Brain Tau Load as Measured by Flortaucipir PET Non-partial Volume Corrected [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    This variable represents how much neurofibrillary tau pathology is present in brain as assessed using positron emission tomography (PET). Scans were conducted using [F18] Flortaucipir, a commonly used tracer in the field.

  30. Solanezumab: Imaging Measures- Brain Atrophy as Measured by Whole Brain Volume Corrected for Head Size [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]
    Brain atrophy was defined by structural magnetic resonance imaging (MRI) A Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequence was processed using the Freesurfer software suite. This package provides volumes and thickness values for cortical regions and volumes for subcortical regions. A whole brain volume measure was generated to represent global atrophy across the cortical and subcortical regions.

  31. Solanezumab: Imaging Measures- Brain Atrophy as Measured by Ventricular Volume (Volumetric MRI) Corrected for Head Size [ Time Frame: Baseline and Weeks 52, 104, 156, 208 and 260 ]
    Rather than looking at how tissue in the brain changes, it is also possible to quantify how the ventricles, fluid filled spaces in the brain, change. Increasing ventricular volume represents greater amounts of cerebral spinal fluid which suggests atrophy of the brain. Magnetization Prepared - RApid Gradient Echo) (MPRAGE) sequences were processed using the Freesurfer software suite. Total ventricular volume was calculated from the ventricular volumes generated by this program.

  32. Solanezumab: Fluid Biomarker Measures- CSF Aβ 40 Free Change From Baseline [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    Measured concentration of the drug bound and free soluble Aβ1-40 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)

  33. Solanezumab: Fluid Biomarker Measures- CSF Aβ 42 Free [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    Measured concentration of the total soluble Aβ 1-42 peptide in cerebrospinal fluid using ELISA

  34. Solanezumab: Fluid Biomarker Measures- CSF Tau [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    Measured concentration of the soluble Tau peptide in cerebrospinal fluid

  35. Solanezumab: Fluid Biomarker Measures- CSF pTau 181 [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    Measured concentration of phosphorylated tau at threonine-181 in cerebrospinal fluid

  36. Solanezumab: Change From Baseline Fluid Biomarker Measures- CSF Neurofilament Light Chain (NfL) [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    Measured concentration of neurofilament light chain in cerebrospinal fluid using SIMO

  37. Solanezumab: Fluid Biomarker Measures- Plasma Neurofilament Light Chain (NfL) [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    Measured concentration of neurofilamnet light chain in plasma using Single Molecule Array (SIMOA)

  38. Solanezumab: Fluid Biomarker Measures- Plasma Anti-drug Antibodies (ADA) [ Time Frame: Baseline and Weeks 52, 104 and 208 ]

    Measurement of the presence or absence of anti-drug antibodies in serum

    Note: Mutation Negative Placebo subjects are not displayed as anti-drug antibody testing was not to be evaluated for these subjects.

    Note: Treatment Emergent Anti-Drug Antibody Positive subjects are defined as those with either (a) a baseline status of ADA Not Present and at least one post-baseline ADA present with a titer >= 1:20 or (b) both a baseline and post-baseline status of ADA Present with the post-baseline titer being 2 dilutions (4-fold) greater than the baseline titer.

    Note: Treatment Emergent Anti-Drug Antibody Inconclusive subjects are defined as those for whom >=20% of the subject's post-baseline ADA results are ADA Inconclusive and all remaining post-baseline samples are ADA Not Present.

    Note: Treatment Emergent Anti-Drug Antibody Negative subjects are defined as those who are evaluable for TE ADA but are neither TE ADA Positive nor TE ADA Inconclusive.


  39. Solanezumab: Fluid Biomarker Measures- Total Plasma Aβ 1-40 [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    Measured concentration of the total soluble Aβ 1-40 peptide in cerebrospinal fluid using ELISA

  40. Solanezumab: Fluid Biomarker Measures- Total Plasma Aβ 42 [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    Measured concentration of the total soluble Aβ 1-42 peptide in cerebrospinal fluid using ELISA

  41. Solanezumab: Fluid Biomarker Measures- CSF Aβ 42 Total [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    Measured concentration of the total soluble Aβ1-42 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)

  42. Solanezumab: Fluid Biomarker Measures- CSF Aβ 40 Total [ Time Frame: Baseline and Weeks 52, 104 and 208 ]
    Measured concentration of the total soluble Aβ1-40 peptide in cerebrospinal fluid using enzyme-linked immunosorbent assay (ELISA)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Between 18-80 years of age
  • Individuals who know they have an Alzheimer's disease-causing mutation or are unaware of their genetic status and have dominantly inherited Alzheimer's disease (DIAD) mutation in their family.
  • Are within -15 to + 10 years of the predicted or actual age of cognitive symptom onset.
  • Cognitively normal or with mild cognitive impairment or mild dementia, Clinical Dementia Rating (CDR) of 0-1 (inclusive)
  • Fluency in DIAN-TU trial approved language and evidence of adequate premorbid intellectual functioning
  • Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron Emission Tomography (PET), and complete all study related testing and evaluations.
  • For women of childbearing potential, if partner is not sterilized, subject must agree to use effective contraceptive measures (hormonal contraception, intra-uterine device, sexual abstinence, barrier method with spermicide).
  • Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
  • Has a Study Partner who in the investigator's judgment is able to provide accurate information as to the subject's cognitive and functional abilities, who agrees to provide information at the study visits which require informant input for scale completion.

Exclusion Criteria:

  • History or presence of brain MRI scans indicative of any other significant abnormality
  • Alcohol or drug dependence currently or within the past 1 year
  • Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan.
  • History or presence of clinically significant cardiovascular disease, hepatic/renal disorders, infectious disease or immune disorder, or metabolic/endocrine disorders
  • Anticoagulants except low dose (≤ 325 mg) aspirin.
  • Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months.
  • History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years.
  • Positive urine or serum pregnancy test or plans or desires to become pregnant during the course of the trial.
  • Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04623242


Locations
Show Show 25 study locations
Sponsors and Collaborators
Washington University School of Medicine
Eli Lilly and Company
Hoffmann-La Roche
Alzheimer's Association
National Institute on Aging (NIA)
Avid Radiopharmaceuticals
Accelerating Medicines Partnership (AMP)
Investigators
Layout table for investigator information
Study Director: Randall J Bateman, MD Washington University School of Medicine
  Study Documents (Full-Text)

Documents provided by Washington University School of Medicine:
Study Protocol  [PDF] December 20, 2019
Statistical Analysis Plan  [PDF] December 20, 2019

Additional Information:
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT04623242    
Other Study ID Numbers: DIAN-TU-001 (gant-sola)
The Alzheimer's Association ( Other Grant/Funding Number: DIAN TTU-12-243040 )
U01AG042791 ( U.S. NIH Grant/Contract )
2013-000307-17 ( EudraCT Number )
R01AG046179 ( U.S. NIH Grant/Contract )
REec-2014-0817 ( Registry Identifier: Spanish Clinical Studies Registry )
The Alzheimer's Association ( Other Grant/Funding Number: DIAN-TU Tau-15-347219 )
GHR Foundation ( Other Grant/Funding Number: File 4401 )
Alzheimer's Association ( Other Identifier: HDE 18S84914 )
First Posted: November 10, 2020    Key Record Dates
Results First Posted: September 22, 2022
Last Update Posted: September 22, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Access to DIAN-TU trial data will follow the DIAN-TU data access policy, which complies with the guidelines established by the Collaboration for Alzheimer's Prevention [CAP REF].
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Keywords provided by Washington University School of Medicine:
Alzheimer's
Alzheimer's Disease
Dementia
Mutation
Genetic Mutation
Dominantly Inherited Alzheimer's Disease
Dominantly Inherited Alzheimer Network
Autosomal Dominant Alzheimer's Disease
Early Onset Alzheimer's Disease
DIAN
DIAN-TU
DIAN TU
DIAD
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs